Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?

Anti-Cancer Agents in Medicinal Chemistry, 10(9): 661-665.

Author(s): Fanny Julia, Luc Thomas, Charles Dumontet and Stephane Dalle.

Affiliation: Unit of Dermatology, Centre Hospitalier Lyon Sud, Chemin du grand revoyet, 69495 Pierre Benite Cedex, France.


Metastatic melanoma is a very aggressive cancer. Dacarbazine has been considered as the standard therapy for decades. Due to a better understanding of melanoma cells signalling and immunological response, new targeted therapies are now proposed. The efficency of these new drugs needs to be confirmed by on larger clinical trials. Ipilimumab (anti-CTLA4 monoclonal antibody) and V600-E- B-raf inhibitor have shown encouraging results, while c-KIT and MEK inhibitors are currently under evaluation. These recently published data shed the light on melanoma management. We review here the latest development of these molecules and the current perspectives in the treatment of metastatic melanoma.


Melanoma, targeted therapy, ipilimumab, c-KIT inhibitor, B-raf inhibitor.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 9
First Page: 661
Last Page: 665
Page Count: 5
DOI: 10.2174/187152010794479834
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science